Introduction
The expanding incidence of antimicrobial resistance among Gram-positive pathogens to a substantial number of antibacterial agents is becoming a major concern.
1 Particularly alarming is the emergence of resistance to glycopeptides, the last line of defence against infections with these organisms. Vancomycin and teicoplanin are traditionally considered the drugs of choice for treatment of Gram-positive infections. In addition, vancomycin cannot be given orally because of poor systemic absorption. Therapeutic issues caused by VRE were initially recognized in the 1980s and in a report by the CDC from 1989 to 1993, the incidence of nosocomial infections due to VRE increased >26-fold and was most apparent in ICUs. 2, 3 In addition, teicoplanin raises concerns about toxicity, requiring continued observation of levels during parenteral administration. 4, 5 The increasing prevalence of MRSA has additionally become a major therapeutic challenge for the hospital infection community and is associated with increased hospital costs and longer hospital stays. 6 Other antibiotics such as aminoglycosides, third-generation cephalosporins, tetracyclines, fluoroquinolones and lincosamides have some activity against community-acquired MRSA strains, 7 but are not sufficiently effective for clinical use in all infections. 8, 9 Thus, expanding treatment options for patients with complicated infections due to such pathogens, especially MRSA, is essential. Commonly, these nosocomial MRSA strains are MDR, making vancomycin the most frequently used therapy for MRSA infections. 6 On the other hand, the increase in vancomycin utilization for these serious infections has recently led to new concern.
Oxazolidinones were discovered by DuPont Pharmaceuticals in the late 1980s, but linezolid, the first analogue suitable for development, was identified only when the family was reexamined by Pharmacia in the 1990s. 10 Subsequently, linezolid was approved and released by the US FDA in April 2000. 11 Significant points of interest of linezolid are the absence of inherent cross-resistance to other antimicrobial classes and the lack of rapid in vitro resistance development. The good clinical outcome and low side effects associated with linezolid indicate that it might be an appealing option for the treatment of infections caused by high-incidence MDR Gram-positive pathogens, such as those causing CNS infections. 12 Considering the importance of linezolid in treating infections caused by Gram-positive bacteria, this study was conducted in order to optimize the clinical use of this antibiotic. To achieve this goal, we evaluated almost all the literature on microbiological and clinical studies in the main databases regarding the mechanisms and prevalence of resistance.
Antibacterial spectrum of activity
Linezolid has demonstrated potent in vitro activity against the vast majority of clinically important Gram-positive cocci, including VRE, as well as MRSA and high-level penicillin-resistant Streptococcus pneumoniae, which may potentially acquire resistance genes from enterococci. 13, 14 Linezolid exhibited in vitro activity against both drug-susceptible and -resistant isolates of Mycobacterium tuberculosis (MTB) with the standard anti-TB agents without cross-resistance. 15 However, its long-term utilization in the treatment of
The release of linezolid, though welcome in order to provide effective treatment for VRE (particularly Enterococcus faecium), also caused a developing requirement for careful, prospective surveillance of resistance to this class in order to restrain further expansion in resistance patterns. 3 The excellent oral bioavailability of linezolid makes it an appealing candidate for the treatment of diseases such as osteomyelitis and endocarditis, for which extended courses of treatment are regularly required for cure (see below). In vitro pharmacodynamic (PD) studies showed that linezolid exhibits minimal bactericidal activity against staphylococci, high bactericidal activity against streptococci and is bacteriostatic against Gram-positive cocci such as enterococci. 21 Early microbiological cure rates determined by Wunderink et al. 22 were not statistically significantly higher with linezolid treatment than with vancomycin treatment despite trends in all secondary clinical results favouring linezolid therapy. These results suggest that any beneficial effect of linezolid therapy might be because of factors other than increased bacterial clearance. Retrospective analysis of two double-blind, prospective, randomized studies of nosocomial pneumonia, including ventilator-associated pneumonia, showed that linezolid treatment was associated with higher survival rates and clinical cure compared with vancomycin treatment in the subset of patients with reported MRSA pneumonia.
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Pharmacokinetic (PK)/pharmacodynamic (PD) properties
The PK/PD parameters most appropriate to characterize the activity of linezolid are T >MIC and the AUC/MIC ratio. 25 Linezolid MICs vary slightly with the test method, laboratory and significance attributed to thin hazes of bacterial survival; however, all specialists find that the susceptibility distributions are narrow and unimodal, with MIC values between 0.5 and 4 mg/L for staphylococci, streptococci and enterococci. For Pasteurella, Moraxella and Bacteroides spp., MICs of 4-8 mg/L were reported. 10 The ability of linezolid to penetrate into the extracellular space fluid of soft tissues is well characterized in critically ill patients and healthy volunteers. 26 Animal and human PK studies have demonstrated that linezolid readily distributes to well-perfused tissues with an extensive volume of distribution at steady-state. 26 Linezolid has demonstrated a mean penetration in epithelial lining fluid of $100%-450% compared with serum. 22 However, the rate and extent of penetration of linezolid into bone tissue is controversial in the medical literature. 27 In healthy subjects, 50%-70% of linezolid is metabolized by the liver, producing two major metabolites devoid of significant antibacterial activities [the aminoethoxyacetic acid metabolite (PNU-142300), and the hydroxylethyl glycine metabolite (PNU-142586)]. 28 As these metabolites are formed, they are excreted via the kidney, which represents the most essential route of excretion. At steady-state, 50% of the dose appears in the urine as the two major metabolites and 30% as linezolid. No parent drug is found in the faeces, whereas faecal excretion accounts for $10% of metabolic clearance. 28, 29 The plasma half-life is in the range of 4-6 h.
PK/PD are essentially modified in critically ill septic patients and the risk of prolonged periods with concentrations below the MIC and of low AUC/MIC ratios is of concern. 30 The PK characteristics of linezolid are not markedly modified by the presence of renal insufficiency and no change of the currently recommended dosage (600 mg twice daily, orally or intravenously) is needed in renal failure. 28, 29 However, compared with those patients with normal renal function, significantly lower platelet counts and haemoglobin levels have been reported in such patients. 31 This suggests that the suitable dose and administration route for linezolid are yet to be established in patients with renal insufficiency. Hence, linezolid is a pharmacodynamically suitable and reasonable drug of choice for the treatment of patients with renal dysfunction who have Gram-positive infection. 32, 33 It was reported that daily half doses of linezolid (600 mg once daily) were effective in the eradication of MTB in patients with intractable or XDR TB (Figure 1) . 34 However, dose reduction did not reduce the risk of neurotoxicity, although it did reduce haematological adverse events and drug cost. A retrospective TB Network European Trials Group (TBNET) assessment reported that the addition of 600 mg of linezolid once daily to an individualized multidrug regimen may enhance the chance of bacteriological conversion, improved the possibility of treatment success in only the most complicated MDR/XDR-TB cases. 35 There is a statistically significant strong correlation between linezolid clearance and creatinine clearance (CL CR ). 36 Also, there is a negative correlation between linezolid clearance and blood urea nitrogen, although the correlation is not statistically significant. 36 According to research, in thrombocytopenic patients the trough concentration was 14.4-35.6 mg/L and the linezolid plasma AUC 24 was 513.1-994.6 mgÁh/L; in non-thrombocytopenic patients, drug exposure was relatively low (294.3-323.6 mgÁh/L for AUC 24 and 6.9-7.2 mg/L for trough concentration). 36 These results give a PK explanation for the mechanism of the adverse event where renal insufficiency increases linezolid AUC and trough concentration such that higher drug exposure induces thrombocytopenia. 32 There is no report regarding the mechanism by which renal failure can result in thrombocytopenia, although it was previously noted that special attention to thrombocytopenia is needed when linezolid is administered to a patient with a CL CR <60 mL/min and/ or blood urea nitrogen >8.21 mmol/L. 37 In that study, linezolidinduced thrombocytopenia occurred with trough concentrations !14.4 mg/L and AUC 24 !513.1 mgÁh/L, causing thrombocytopenia in a concentration-dependent manner. 36 Therefore, linezolid overdose is a major concern, although the appropriate dose and administration method for ensuring the efficacy and safety of linezolid have yet to be clarified.
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Mechanism of action
Early work by DuPont scientists and coworkers demonstrated that oxazolidinones inhibited protein synthesis but not that of DNA or RNA. 38 This information, coupled with the observations of many laboratories that the oxazolidinones lacked cross-resistance with existing antimicrobial agents, suggested that the mechanism of action of the oxazolidinones was likely unique. Unlike other protein synthesis inhibitors, linezolid appears to block formation of the initiation complex during protein synthesis. The initiation phase of protein synthesis was focused on as a plausible site of inhibition as various authors reported that polysome elongation, binding of mRNA to ribosomes and termination of translation was not inhibited by oxazolidinones. 38, 39 Oxazolidinones bind to the 50S subunit of the prokaryotic ribosome, preventing it from complexing with the mRNA, 30S subunit, fMet-tRNA and initiation factors 2 and 3. 38, 40, 41 The net outcome is to block assembly of a functional initiation complex for protein synthesis, thereby preventing translation of the mRNA ( Figure 2 ). This mode of action differs from that of existing protein synthesis inhibitors such as chloramphenicol, macrolides, lincosamides and tetracyclines, which allow mRNA translation to begin but then inhibit peptide elongation. This difference may appear academic, but might be noteworthy in two regards. First, linezolid seems particularly effective in preventing the synthesis of streptococcal and staphylococcal virulence factors (e.g. haemolysins, coagulase and protein A), perhaps due to its mode of action. 42 Second, linezolid has a target that does not overlap with those of existing protein synthesis inhibitors; consequently, its activity is unaffected by the rRNA methylases that alter the 23S rRNA so as to block the binding of clindamycin, macrolides and group B streptogramins.
Mechanism of resistance
Because linezolid is a completely synthetic drug, no natural reservoir of resistance genes would be expected to favour the presence of clinical resistance. Actually, the primary reports of bacteria resistant to linezolid demonstrated the presence of point mutations at the drug target site. Among the detected cases of linezolid resistance reported among staphylococci and enterococci, G2576T (position 2576 refers to the nucleotide position originally assigned to rRNA genes in E. coli), G2447T or T2504A 23S rRNA target site mutations have been most prevalent ( Figure 2c and d and Figure 3 ). [43] [44] [45] However, different mutations have been found in clinical isolates and in vitro, demonstrating that resistance was clearly generated de novo through spontaneous mutations rather than genetic exchange. Additional mutations observed in resistant isolates include T2500A, C2192T, A2503G, T2504C, C2461T, G2505A, G2766T 46 and G2061T. 47 The resistance pattern is organism specific in that the obtained mutation sites differ, with only little overlap between E. coli, Halobacterium halobium, Mycobacterium smegmatis, MTB, Enterococcus faecalis, Enterococcus faecium, S. pneumoniae and Staphylococcus aureus ( Figure 3 shows detailed information). The above-mentioned mechanisms of linezolid resistance have been shown not to be transmissible between species and are associated with previous exposure to linezolid. Therefore, spontaneous linezolid resistance appears in vitro at very low rates, 48 as evidenced by the infrequent finding of linezolid-resistant clinical isolates of S. aureus. 49 Mutations in the central loop of domain V of 23S rRNA and the ribosomal proteins L3 and L4, which are mainly due to prolonged exposure to this agent, have been associated with resistance to linezolid in several species. 50, 51 Resistance develops slowly, because nearly all bacteria possess multiple copies of the 23S rRNA gene (S. aureus strains have five or six operons encoding 23S rRNA). 52 However, in contrast to many reports indicating that such resistant isolates arise only after prolonged therapy with this antibiotic, a study has shown rapid emergence of resistance to linezolid; 53 therefore, close monitoring of strain susceptibilities is advisable.
The cfr (chloramphenicol/florfenicol resistance) gene has emerged as a novel mechanism of non-mutational resistance to several antimicrobial classes including linezolid. 54 The mobile cfr gene is a plasmid-encoded protein that appears to be capable of horizontal transfer between staphylococci and was initially identified in a bovine Staphylococcus sciuri from the late 1990s ( Figure  4) . However, the 2005 Colombian MRSA isolate CM05 was the first report of a clinical cfr-positive strain and this gene has now been detected in staphylococci and isolates of CoNS cultured from human infections on several continents. 46, 55, 56 The product of the cfr gene is a methyl transferase that catalyses methylation of the C8 atom of A2503 in the 23S rRNA gene of the large ribosomal subunit, leading to resistance to chloramphenicol, clindamycin and florfenicol. 57 Dissemination of the cfr gene would reduce the efficacy of linezolid for treating infections caused by resistant Grampositive bacteria. Currently, to prevent further dissemination of this resistance mechanism, an effective nosocomial infection control strategy, monitoring of colonization by these resistant isolates and reinforcement of hand hygiene as well as a principle of judicious use of antibiotics, should be established to prevent further spread of this resistance mechanism in the world.
Recently, the new oxazolidinone resistance gene optrA has been identified in E. faecalis and E. faecium isolates of human and . PK of linezolid exposure was measured for patients while they were getting 600 mg every day and for all patients who in this way got 300 mg every day. Plasma concentrations for the four patients in whom resistant bacteria developed are indicated in grey and the dose the patient was taking at the time of resistance detection is shown by circles (300 mg) or triangles (600 mg). The linezolid MIC for the initial isolates from the patients and the mean MIC (horizontal line) are indicated on the right. 126 Reproduced with permission from the Massachusetts Medical Society.
Review animal origin. 58 This gene codes for an ATP-binding cassette (ABC) transporter that confers resistance to or elevated MICs of oxazolidinones (tedizolid and linezolid) and phenicols (florfenicol and chloramphenicol). However, the exact mechanism by which this ABC transporter confers resistance to oxazolidinones and phenicols is not fully understood as it lacks a membrane component.
The optrA gene is the first identified transferable gene that confers an elevated MIC of tedizolid, a recently approved novel oxazolidinone with improved activity against linezolid-resistant isolates carrying the cfr gene. 59, 60 In two Chinese studies, optrA was found in 2.0%-2.9% of the tested clinical E. faecalis and E. faecium isolates collected from five hospitals (2010-14) . 58, 61 In addition, the newly Only mutations where some evidence or strong indication of the mutation-resistance relationship has been published are shown.
Review JAC described resistance mechanism, the optrA gene, was discovered in E. faecalis from Ireland and Malaysia, 62 showing that enterococci carrying optrA are not limited to China.
Risk factors for the development of linezolid resistance include previous linezolid consumption, receipt of a solid organ transplant, immunosuppression and previous surgery. 63 Particularly, caution should be exercised when utilizing linezolid to treat undrained or partially drained collections, when targeting infected places with poor penetration of the drug or infected foreign bodies, when utilizing lengthy and repeated courses or when using linezolid for longterm suppression.
63,64
Laboratory methods for identification
Screening and antibiotic susceptibility testing of isolates places a heavy, but necessary, burden on microbiology laboratories. Broth microdilution is the reference method used for routine laboratory measurement of the linezolid MIC. 65 However, the epidemiological interest of linezolid-resistant isolates requires characterization of the particular resistance mechanism involved, generally at referral centres. The disc diffusion method is not appropriate for recognizing linezolid resistance mediated by the cfr gene with the current EUCAST or CLSI breakpoints. 66 According to the data, staphylococcal isolates showing a resistant phenotype to chloramphenicol, clindamycin and linezolid may have a possible presence of cfr gene. However, further molecular examinations are required due to the low cfr prevalence observed in the most studied population. 66 Other linezolid resistance mechanisms, non-cfr mediated, are possible, but they do not necessarily involve chloramphenicol and clindamycin resistance. Standard methodology is to perform PCR followed by DNA sequencing analysis of the region involved. 67 Molecular epidemiology and resistance mechanism (various target mutations or cfr) testing for linezolid-resistant strains show that, in a number of monitored medical centres, linezolid resistance has been consistently experienced over several years. All linezolid-resistant strains had detectable resistance mechanisms, which were accounted for by ribosomal rRNA, ribosomal protein (L3, L4 and L22) and/or cfr mutations. 45 Pyrosequencing was an effective and rapid method for detecting and estimating copy numbers of the G2576T polymorphism in linezolid-resistant enterococci. It might also be useful for detecting this SNP in linezolid-resistant isolates of MRSA. 68 Pyrosequencing was somewhat quicker than the realtime PCR assay reported previously and had the additional benefit of being semi-quantitative.
Linezolid treatment for complications
Linezolid was used in previous studies to treat patients with skin and soft-tissue infections and osteomyelitis due to Gram-positive cocci who were unable to tolerate glycopeptides or whose pathogens were resistant to these antimicrobial agents. [69] [70] [71] In addition, this antibiotic is an attractive choice for use in combination with rifampicin due to its broad-spectrum activity against most Grampositive cocci, its oral formulation and its concentrations exceeding the MIC for susceptible organisms ( 4 mg/L) observed in soft tissue and bone. 71, 72 Community-acquired MRSA has become a major cause of complicated skin and soft-tissue infections 73 and is a significant cause of morbidity and mortality in hospitalized patients. These developments have prompted MRSA isolates to be declared a serious threat to public health. Although treatment alternatives for MRSA are available, challenges or limitations exist, which include (but are not limited to) drug-drug interactions, safety concerns, need for dose adjustments and the existence or development of resistance. According to the data, linezolid is well tolerated and as effective as oxacillin/dicloxacillin for such complicated infections, with the additional advantage of convenient twice-daily dosing administered either intravenously or orally. 74 Oral linezolid may be an effective agent for the eradication of MRSA colonization in selected patients with cystic fibrosis. 75 Moreover, the oral formulation of linezolid has a definite economic advantage over vancomycin, allowing reduced cost of outpatient care and earlier hospital discharge. 76 However, a large, multicentre trial is expected to confirm the economic and clinical efficacy of oral linezolid in the management of these lower-extremity infections. Finally, based on PK/PD considerations, we can comprehend that free concentrations of linezolid are adequate to cover soft-tissue and bone infections with MRSA or other Gram-positive bacteria commonly isolated in patients with diabetic foot infections complicated by osteomyelitis. 
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Prevalence of resistance
The history of linezolid surveillance programmes began several years before product launch with a series of in vitro susceptibility testing studies, including the ZyvoxV R Appraisal of Potency and Spectrum (ZAAPS) international studies that were initiated before the US FDA release of this product. 77 Oxazolidinone resistance surveillance for the USA was originally provided by the 2002 and 2003 ZAAPS programme that inspected nations around the globe including the USA. However, the 2004-10 ZAAPS programme sampled only nations other than the USA, while the USA component was separated into the LEADER programme and extended to !60 laboratory sites in an effort to concentrate on emerging resistance development in different regions in the USA. 45 The LEADER surveillance programme has monitored linezolid activity, spectrum and resistance rates in the USA since 2004. 45 Therefore, it is prudent to routinely monitor the in vitro activity of linezolid and possible evolving resistances as its use expands worldwide.
No linezolid-resistant Gram-positive cocci were found in the many in vitro surveys performed before licensing; moreover, mutational linezolid resistance is extremely difficult to select in vitro.
15
Like earlier companion ZAAPS programme reports, linezolid resistance in the USA among Gram-positive pathogens remained significantly <1.0% (actual rate for 2010 was 0.38%). 45 However, the prevalence of antibiotic resistance is increasing in many countries (Table 1) . According to the LEADER surveillance programme that was conducted on 7429 Gram-positive pathogens during 2012, linezolid showed potent activity when tested against S. aureus, inhibiting 2980 isolates at 2 mg/L, except for 3 S. aureus.
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Similarly, linezolid showed coverage against 99.5% of enterococci, as it did for all streptococci tested. 63, 79 These results confirm a long record of linezolid activity against US Gram-positive isolates since regulatory approval in 2000. 78 The ZAAPS programme has studied and documented the spectrum and activity of linezolid tested against Gram-positive pathogens for nine sequential years , except in the USA. 80 In this survey, a total of 7972 isolates were sampled from 33 countries (73 medical centres) on five continents: all streptococci remained very susceptible to linezolid, while a very limited number of non-susceptible isolates were observed among enterococci and staphylococci, especially Staphylococcus epidermidis. Molecular analysis indicated that nonsusceptible isolates of enterococci and S. aureus seem to be scattered across various surveyed sites and are likely to reflect random selection due to previous and/or prolonged use of linezolid. 81 In contrast, some oxazolidinone-resistant strains have emerged in patients not previously exposed to linezolid therapy and have been attributed to clonal or epidemic spread in the hospital environment. 82 The linezolid-resistant CoNS collected within each institution were invariably clonally associated with one or more isolates observed in recent surveillance years, indicating a persistence of endemic clones. Moreover, that study reported the first identification of a cfr-carrying S. aureus from Brazil, which was considered susceptible to linezolid (MIC 4 mg/L) when applying EUCAST or CLSI breakpoints, emphasizing the significance of active surveillance programmes. 80 Worldwide, the incidence of linezolid-resistant CoNS is currently 28 times that of linezolid-resistant S. aureus.
83
In the first report of clinical linezolid-resistant MRSA in the USA (2001), three isolates (linezolid MIC >32 mg/L) were sampled from a patient treated for dialysis with peritonitis of, which two isolates were indiscernible from each other by PFGE and the third differed by a single band. 43 The second, in 2003, included a patient in the UK who experienced thoracotomy and drainage of empyema; 84 distinct populations of MRSA containing some colonies that were linezolid susceptible (MIC 1-2 mg/L) and others that were linezolid resistant (MIC 8-32 mg/L) were isolated. In this case, linezolid resistance emerged from a susceptible strain during treatment. 85 Clinical reports of linezolid resistance date from 2007 when Toh et al. 86 reported the first cfr-mediated linezolid-resistant clinical isolate of MRSA. Since then, notable reports have included two US-based cases of cfr-mediated resistance in clinical isolates of S. aureus and S. epidermidis in 2008, 87 a 2013 case report of a cfrcarrying MRSA blood culture isolate from an ICU in Barcelona, Spain 66 and characterization of cfr-mediated Staphylococcus haemolyticus and MRSA with fatal outcomes originating from a German group. 88 In a Spanish study, a very low prevalence of cfrmediated linezolid resistance was found: only 1 bacteraemic isolate out of 2215 screened isolates, which was due to the patient's previous linezolid therapy. 66 It can be inferred that despite the low rate of resistance worldwide, ongoing surveillance is advisable to avoid the spread of linezolid resistance. So, according to different studies performed worldwide (Table 1) , antibiotic susceptibility patterns of Gram-positive isolates vary in different areas; knowledge of this pattern in each area is crucial for selection of the best treatment of infections caused by these organisms.
Efficacy and safety
Despite the well-demonstrated clinical and bacteriological efficacy of linezolid in a few clinical trials in adults and children with bacteraemia, nosocomial pneumonia and skin and soft-tissue infections, 23, 89, 90 data to support its utilization in treating more complex infections such as orthopaedic infections are limited. There are some side effects associated with linezolid therapy including diarrhoea, headache, nausea, vomiting and reversible myelosuppression (mostly thrombocytopenia); these were reported for both linezolid and comparators during Phase III comparator-controlled trials. 77, 91 In Phase III studies, 1.5% of patients treated with comparator drugs and 2.4% of patients treated with linezolid developed reversible thrombocytopenia (P ¼ 0.066); however, there was no evidence of an increased risk of aplastic anaemia, agranulocytosis or other irreversible blood dyscrasias. 92 The mechanism of the anaemia has been described and is thought to be due to inhibition of mitochondrial respiration, 93 which can be managed relatively easily with transfusions. The thrombocytopenia is progressive and may lead to cessation of drug use; a mechanism for this effect has not been described. Recent studies have reported that the incidence of linezolid-induced thrombocytopenia was higher in patients with renal failure than in patients with normal renal function, although no underlying mechanism has been proposed for the thrombocytopenia. 32, 33 The effect of renal insufficiency on erythrocyte and platelet counts in patients undergoing linezolid treatment is still to be elucidated. The microbiological and clinical efficacy of linezolid are not altered in patients with renal dysfunction and therefore no dosage alteration is required. Monitoring the platelet count more than once a week is strongly recommended in patients with renal insufficiency on linezolid treatment for >2 weeks. 32 In addition, patients receiving Review JAC linezolid for >28 days should be monitored for signs of peripheral and optic neuropathy. 94 Linezolid should be used with caution in patients taking serotonergic or adrenergic agents or in those with uncontrolled hypertension. 92 The post-marketing occurrence of any type of haematological toxicity has been reported to be 1 in 750 exposed patients, while the occurrence of anaemia and thrombocytopenia have been reported to be 1 in 2900 and 1 in 1700 exposed patients, Mutations in G2576 and G2534 of the 23S rRNA gene were most common. Review respectively. 95 An early report suggested that the anaemia might be due to a mechanism similar to that of chloramphenicolinduced myelosuppression. 96 There appear to be two distinct mechanisms for linezolid-induced cytopenias. While anaemia is manageable and reversible with transfusions, thrombocytopenia can be a treatment-limiting toxicity. The ability to treat through immune-mediated cytopenia with intravenous immunoglobulin might be beneficial for critically ill patients with few therapeutic options. 93 
Newer oxazolidinones
Tedizolid, the second oxazolidinone approved by the FDA, is a novel oxazolidinone antibacterial drug designed to provide improved activity against Gram-positive pathogens. 97 Tedizolid could become a valuable alternative for the treatment of acute bacterial skin-structure infections in both the hospital and outpatient settings. In vitro, tedizolid is more active against enterococci and staphylococci than linezolid. 98 Also, newer oxazolidinones such as TR-700, DA-7867, RBx 7644, RBx 8700 and DA-7157 have better in vitro activity against MTB 98, 99 and might be better drugs for TB treatment than linezolid. RWJ-416457, another novel oxazolidinone, had modal MICs of 0.5-1 mg/L for linezolidsusceptible staphylococci and enterococci versus linezolid MICs for these organisms of 1 or 2 mg/L. 100 RWJ-416457 MICs for mutants with 23S rRNA mutations were 2-32 mg/L versus linezolid MICs of 8-64 mg/L; actual values reflected the proportion of gene copies mutated. 100 
Conclusions
Linezolid is endowed with a number of favourable characteristics including: a spectrum of activity against MDR agents (methicillin-or vancomycin-resistant strains of S. aureus and S. epidermidis, vancomycin-resistant strains of E. faecalis and E. faecium and penicillin-resistant pneumococci); good tissue penetration into skin, bone, muscle, fat, alveolar cells, lung extracellular lining fluid, blister fluids and cerebrospinal fluid; and 100% bioavailability when administered by either the parenteral or oral route. In addition, it has a unique mechanism of action involving inhibition of protein synthesis at a very early stage (the 23S rRNA of the 50S ribosomal subunit on the bacterial ribosome), which avoids cross-resistance with existing antimicrobials. In addition, linezolid continues to be an important antimicrobial agent with near-complete activity (0.05% resistance). Post-marketing surveillance to detect emerging linezolid resistance should be regarded as a prudent public health practice. The expanded molecular processing of oxazolidinone-resistant isolates in post-marketing surveillance programmes has additionally widened our comprehension of the ribosomal targets and mutations necessary to elevate oxazolidinone MIC values above the WT spectrum. Finally, clinical laboratories should test linezolid more widely to detect emerging resistance, particularly for patients receiving oxazolidinone therapy.
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